• Adia Nutrition’s unit Adia Med began recruiting on ClinicalTrials.gov for two patient-paid studies of AdiaVita, an umbilical cord blood-derived stem cell and exosome product, in chronic kidney disease and chronic lower back pain.
• Enrollment is capped at 100 participants per study, with participation fees of $15,000 for the kidney study and $5,000 for the back pain study.
• Full enrollment would generate $2 million in aggregate proceeds for Adia Med, based on the stated fee structure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adia Nutrition Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202605201158NEWSFILECNPR____20260520_298208_1) on May 20, 2026, and is solely responsible for the information contained therein.